Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for October 06, 2011 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



AstraZeneca, GSK to speak at Anti-infectives Partnering meeting Nov 7-8, Boston
John H Rex, Vice President at AstraZeneca and David J. Payne, Vice President at GlaxoSmithKline will give keynote presentations at the 8th Anti-infectives Partnering and Deal-making Conference to be held in Boston, MA on November 7-8, 2011 by GTC. 
x-small text small text medium text large text


    MONROVIA, CA, October 06, 2011 /24-7PressRelease/ -- John H Rex, Vice President at AstraZeneca and David J. Payne, Vice President at GlaxoSmithKline will give keynote presentations at the 8th Anti-infectives Partnering and Deal-making Conference to be held in Boston, MA on November 7-8, 2011 by GTC.

John H. Rex will give a keynote speech on "Evaluating Antibacterial Opportunities: Practical Advice" and David J. Payne will his keynote speech on "Approaches for Overcoming the Challenges of Antibacterial R&D."

The sessions for the conferences are:
Session I - Recent Advances in Anti-Infectives Development - Part I - Anti-bacterial
Session II - Novel Technologies in Anti-Infectives
Panel Discussion - Investments and Partnerships in the Anti-Infectives Space
Session III - Recent Advances in Anti-Infectives Development - Part II
Session IV - Regulatory Updates
Session V - Innovative Partnering & Licensing Strategies
Session VI - Current Models of Deals in Infectious Diseases

Dr. Rex participated in a variety of clinical trials that investigate the utility of new antifungal agents in human infection. His work in this area has focused primarily on invasive fungal infections of the critically-ill non-neutropenic adult. Also Dr. Rex's laboratory is involved in a variety of studies on the technical aspects of in vitro susceptibility testing. He is a member of the National Committee for Clinical Laboratory Standards' Antifungal Susceptibility Testing Subcommittee. Through the work done in his laboratory with this committee, he has had the opportunity to participate in the development of the M27 and M38 documents on susceptibility testing of yeasts and moulds, respectively. His laboratory uses animal models of invasive fungal infections to investigate better ways to treat these infections in humans. He and colleagues investigate both new drugs and new ways to better use old drugs. These studies are often directly tied to better understanding of ways to use in vitro susceptibility testing to predict response to infection.

Dr. Payne has 21 years of experience in antibacterial drug discovery and is currently Vice
President and Head of the Antibacterial Discovery Performance Unit (DPU) within the Infectious Diseases Centre of Excellence in Drug Discovery (ID CEDD) where he is responsible for GSK's antibacterial research effort from discovery to clinical proof of concept (up to Phase II clinical trials). At GSK, Dr Payne has played a leading role in redesigning the strategy for antibacterial research and has helped create long-term alliances with innovative biotechnology companies which has expanded GSK's discovery pipeline. Furthermore, he has created industry-leading partnerships with the Wellcome Trust and the Defense Threat Reduction Agency (US Department of Defense) to accelerate GSK's antibacterial programmes. To date, Dr Payne has been involved with the progression of a broad diversity of novel mechanism antibacterial agents into development.

The 8th Anti-infectives Partnering and Deal-making Conference gives global biotechnology and pharmaceutical companies in the infectious diseases industry an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant infectious disease issues and partnerships that will affect the industry.

The conference is part of the Infectious Diseases World Summit, which consists of 2 tracks including the 9th Vaccines Discovery and Development: All Things Considered Conference.

For more information, please visit http://www.gtcbio.com

ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #


Read more Press Releases from Rania Hafez:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Rania Hafez
GTCbio

Marketing Director
434 W. Foothill Blvd.
Monrovia, CA
USA 91106
Voice: 626-256-6405
Fax: 626-256-6460
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.